Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
| Status: | Recruiting |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | November 12, 2018 |
| End Date: | August 24, 2022 |
| Contact: | Novartis Pharmaceuticals |
| Email: | novartis.email@novartis.com |
| Phone: | 1-888-669-6682 |
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
This is a multi-center, phase II study to determine the efficacy and safety of
tisagenlecleucel in adult patients with relapsed or refractory FL.
tisagenlecleucel in adult patients with relapsed or refractory FL.
Inclusion Criteria:
- Refractory or relapsed Follicular Lymphoma (Grade 1, 2, 3A)
- Radiographically measurable disease at screening
Exclusion Criteria:
- Evidence of histologic transformation
- Follicular Lymphoma Grade 3B
- Prior anti-CD19 therapy
- Prior gene therapy
- Prior adoptive T cell therapy
- Prior allogeneic hematopoietic stem cell transplant
- Active CNS involvement by malignancy
We found this trial at
6
sites
1150 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
Principal Investigator: Monalisa Ghosh
Phone: 734-615-4762
Click here to add this to my saved trials
Chicago, Illinois 60637
Principal Investigator: Peter Riedell
Phone: 773-834-8980
Click here to add this to my saved trials
Duarte, California 91010
Principal Investigator: Leslie Popplewell
Click here to add this to my saved trials
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Nathan Fowler
Phone: 713-792-2171
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Stephen Schuster
Phone: 215-615-6721
Click here to add this to my saved trials